Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 18, 2006

View Archived Issues

Snapshots on natural products in dermatology

NeuroMedix advances preclinical testing of Alzheimer's candidate Minozac

Advancis plans NDA filing for Amoxicillin PULSYS

Transition Therapeutics and JDRF partner on GLP1-I.N.T.

DDP-733 studies in phase Ib trial for GERD

FDA Advisory Committee votes against approval of Factive for ABS

ARRY-358: Novel MEK inhibitor effective in preclinical DHT

PC-DAC:Exendin-4 safe, with positive efficacy on glucose reduction in diabetics

Early efficacy trends demonstrated for RSD-1235 (oral) in atrial fibrillation

Two-year data show treatment effect of Campath in MS

Atu-027 RNAi shows efficacy in animal models of pancreatic cancer

Evotec discontinues EVT-301 development following liver function findings

Prometic reports progress on two key programs

Long-term pivotal study of Technosphere Insulin completes enrollment

GX15-070 enters phase II for cancer

Biogen Idec to develop, manufacture and commercialize aviptadil

TopoTarget to launch Savene in Europe ahead of schedule

HuMax-EGFr begins phase III trial in refractory head and neck cancer

Banyu and Teijin Pharma launch once-weekly alendronate products in Japan

Japanese launch for Temodal

Novel antiinfective agents disclosed in recent patent literature

Recent Pfizer and Ajinomoto patents describe new treatment strategies for cardiovascular diseases

Novel agents for anxiety, schizophrenia, etc., found in recent patents

BMS reports on novel dual angiotensin I and endothelin A receptor inhibitors

Novel dual KDR/FGFR inhibitors presented at the ACS meeting

Snapshots on novel hepatitis C virus polymerase inhibitors presented at the ACS meeting

Cytokinetics presents preclinical data on novel cardiac myosin activator CK-1316719

Nemod Biotherapeutics reports on a potent new antitumor-specific MUC1 antibody

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...